Bedrijfsoverzicht
AtriCure, Inc. is a specialized developer, manufacturer, and seller of surgical devices utilized for cardiac tissue ablation, the exclusion of the left atrial appendage, and the temporary blocking of pain via peripheral nerve ablation. These medical instruments are distributed to healthcare centers operating across the United States, the Asia-Pacific region, and various international markets within the healthcare sector. The company operates specifically within the industry of Medical Instruments & Supplies, a segment focused on providing essential tools for surgical procedures. In terms of scale, AtriCure holds a market capitalization of $1.43 billion, generates annual revenue of $534.53 million, and employs a workforce of 1,350 individuals. These financial figures indicate that the company has established a significant presence in the medical device landscape, reflecting a substantial valuation relative to its sales volume and a mature operational structure supported by a sizeable team. The market cap suggests that the market values the company's intellectual property and market position highly, while the revenue figure demonstrates the breadth of its sales reach across multiple geographic territories.
Financiële gezondheid
AtriCure reported a trailing twelve-month revenue of $534.53 million, yet it recorded a net income loss of $11,448,000 and an EBITDA of $11.08 million during the same period. The substantial gap between the positive revenue figure and the negative net income reveals a cost structure where operating expenses, including research and development or general administrative costs, are exceeding the gross profit generated from sales. Despite the reported net loss, the company generated positive free cash flow of $38.94 million, which indicates strong financial flexibility and an ability to fund operations without relying on external financing. The company maintains a robust liquidity position with $167.43 million in cash on hand, significantly outweighing its total debt obligation of $76.42 million. This disparity between cash and debt is further supported by a debt-to-equity ratio of 15.54, suggesting a conservative balance sheet with minimal leverage relative to its equity base. The current ratio stands at 3.96, indicating that the company possesses ample short-term assets to cover its current liabilities without difficulty. However, the return on equity is -2.4% and the return on assets is -0.9%, metrics that reveal that management has not yet achieved profitability on the capital invested, reflecting the high costs associated with growth or development phases.
Waarderingsbeoordeling
The valuation metrics for AtriCure present a complex picture, with a trailing P/E ratio listed as N/A due to the lack of positive net income, while the forward P/E ratio is calculated at 76.38. This significant divergence between the unavailable trailing multiple and the high forward multiple implies that the market is pricing in substantial expected future earnings growth to justify the current stock price. The price-to-book ratio is 2.86, which indicates that the market values the company at nearly three times its book value, suggesting a premium assigned to its intangible assets or future revenue potential. Additionally, the price-to-sales ratio stands at 2.67 and the EV/EBITDA is 118.65; these alternative valuation metrics suggest that the market is willing to pay a high multiple for revenue and earnings before interest, taxes, depreciation, and amortization relative to the company's market size and cash generation capabilities. Regarding price momentum, the stock has traded within a 52-week range between a low of $27.26 and a high of $43.18. To determine the current position within this range, one must observe that the stock is trading at a level that reflects recent volatility but remains below the peak of $43.18. The beta value of 1.43 indicates that the stock's price volatility is significantly higher than that of the broader market, meaning the share price tends to move more aggressively than the overall index.
Growth & Income
AtriCure demonstrated a revenue growth rate of 13.1% year-over-year, while the earnings growth rate is listed as N/A due to the company's recent net loss position. The fact that revenue is growing while earnings are negative implies that the company is prioritizing top-line expansion and market capture over immediate profitability, a common strategy in capital-intensive medical device sectors. As a non-dividend payer, the company does not distribute a dividend yield or utilizes a payout ratio, meaning the firm reinvests all of its earnings and cash flow back into the business to fund innovation and growth initiatives. This reinvestment strategy aligns with the company's need to sustain its development efforts for new ablation devices and expand its international footprint. The overall growth and income profile is characterized by strong double-digit revenue expansion and a complete absence of dividend income, reflecting a capital allocation focus on long-term market positioning rather than current income generation for shareholders.